BUDGET IMPACT ANALYSIS OF TRASTUZUMAB EMTANSINE FOR RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN ARGENTINA

被引：0
|
作者：
Penayo, N. [1 ]
Peredo, S. [2 ]
Olivera, M. S. [1 ]
Weissberg, A. [1 ]
Tellechea, F. [1 ]
Saenz, V [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Tigre, Argentina
[2] F Hoffmann Roche Ltd, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN62
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [41] Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Shanshan Hu
    Yilai Wu
    Jiajie Luan
    Shuowen Wang
    Guorong Fan
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17933 - 17942
  • [42] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
    Guerin, Mathilde
    Sabatier, Renaud
    Goncalves, Anthony
    BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
  • [43] Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies
    Dieras, V.
    Harbeck, N.
    Budd, G. T.
    Greenson, J. K.
    Guardino, E.
    Samant, M.
    Chernyukhin, N.
    Smitt, M.
    Krop, I. E.
    CANCER RESEARCH, 2012, 72
  • [44] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer (vol 80, pg 1723, 2020)
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (18) : 2001 - 2001
  • [45] BUDGET IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER IN SPECIALTIES HOSPITAL IN ECUADOR
    Irigoyen, P.
    Moreno, A.
    Gavilanes, C.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [46] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
    Khattak, Monica N.
    Chichura, Anna M.
    Lang, Julie E.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1423 - 1427
  • [47] Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Hu, Shanshan
    Wu, Yilai
    Luan, Jiajie
    Wang, Shuowen
    Fan, Guorong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 17933 - 17942
  • [48] Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study
    Rojo Todo, F.
    Stradella, A.
    Garcia-Saenz, J. A.
    Bermejo De Las Heras, B.
    Alfonso Romero, J. L.
    Barnadas, A.
    Izarzugaza Peron, Y.
    Alba, E.
    Lopez-Tarruella, S.
    Henao-Carrasco, F.
    Carrasco, E.
    Caballero, R.
    Del Campo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S391 - S391
  • [49] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
    Monica N. Khattak
    Anna M. Chichura
    Julie E. Lang
    Annals of Surgical Oncology, 2024, 31 : 1423 - 1427
  • [50] Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
    Waks, Adrienne G.
    Keenan, Tanya E.
    Li, Tianyu
    Tayob, Nabihah
    Wulf, Gerburg M.
    Richardson, Edward T.
    Attaya, Victoria
    Anderson, Leilani
    Mittendorf, Elizabeth A.
    Overmoyer, Beth
    Winer, Eric P.
    Krop, Ian E.
    Agudo, Judith
    Van Allen, Eliezer M.
    Tolaney, Sara M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
12345